A detailed history of Brinker Capital Investments, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 28,138 shares of LLY stock, worth $25.7 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
28,138
Previous 27,843 1.06%
Holding current value
$25.7 Million
Previous $9 Million 14.34%
% of portfolio
0.21%
Previous 0.19%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

BUY
$321.55 - $374.67 $94,857 - $110,527
295 Added 1.06%
28,138 $10.3 Million
Q3 2022

Nov 01, 2022

BUY
$296.48 - $337.87 $355,183 - $404,768
1,198 Added 4.5%
27,843 $9 Million
Q2 2022

Jul 18, 2022

SELL
$278.73 - $327.27 $646,374 - $758,939
-2,319 Reduced 8.01%
26,645 $8.64 Million
Q1 2022

May 16, 2022

SELL
$234.69 - $291.66 $102,090 - $126,872
-435 Reduced 1.48%
28,964 $8.29 Million
Q4 2021

Feb 08, 2022

BUY
$224.85 - $279.04 $1.19 Million - $1.48 Million
5,309 Added 22.04%
29,399 $8.12 Million
Q2 2021

Aug 03, 2021

BUY
$180.55 - $233.54 $966,303 - $1.25 Million
5,352 Added 28.56%
24,090 $5.53 Million
Q1 2021

May 12, 2021

SELL
$164.32 - $212.72 $3.34 Million - $4.33 Million
-20,345 Reduced 52.06%
18,738 $3.5 Million
Q4 2020

Feb 16, 2021

BUY
$130.46 - $172.63 $2.71 Million - $3.59 Million
20,769 Added 113.41%
39,083 $6.6 Million
Q3 2020

Dec 03, 2020

BUY
$146.22 - $169.13 $2.68 Million - $3.1 Million
18,314 New
18,314 $2.71 Million
Q1 2020

May 13, 2020

SELL
$119.05 - $147.35 $82,977 - $102,702
-697 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$106.79 - $116.16 $1,601 - $1,742
-15 Reduced 2.11%
697 $78,000
Q2 2019

Aug 14, 2019

SELL
$110.79 - $129.32 $10,192 - $11,897
-92 Reduced 11.44%
712 $79,000
Q1 2019

May 14, 2019

BUY
$111.31 - $131.02 $89,493 - $105,340
804 New
804 $104,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $869B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Brinker Capital Investments, LLC Portfolio

Follow Brinker Capital Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.